Augmented cholescintigraphy: its role in detecting acute and chronic disorders of the hepatobiliary tree.
Cholecystagogue cholescintigraphy can be employed as a means of (1) confirming the surgeon's and/or gastroenterologist's clinical impression of symptomatic chronic acalculous biliary disease, (2) better understanding the pathophysiology of gallbladder disease, (3) preparing patients for hepatobiliary scintigraphy who have fasted for longer than 24-48 hours and who are suspected of acute cholecystitis, and (4) reducing the time required to confirm the clinical impression of acute cholecystitis. Morphine-augmented cholescintigraphy is also used to decrease the time required to determine cystic duct patency. Phenobarbital-augmented cholescintigraphy is used as a means of increasing the accuracy of hepatobiliary scintigraphy in differentiating neonatal hepatitis from biliary atresia. Nonpharmacological interventions and augmentations have been employed to maintain the high degree of accuracy of cholescintigraphy in confirming the clinical impression of acute cholecystitis. The efficacy of these modalities in detecting acute and chronic disorders of the hepatobiliary tree as well as how and why they are performed comprise the contents of this article.
Fink-Bennett
D
D
Nuclear Medicine Department, William Beaumont Hospital, Royal Oak, MI.
D001660:Biliary Tract Diseases / Q000000981:diagnostic imaging*; D002766:Cholecystokinin; D006801:Humans; D007231:Infant, Newborn; D007567:Jaundice, Neonatal / Q000000981:diagnostic imaging*; D009020:Morphine; D010634:Phenobarbital; D011877:Radionuclide Imaging
D009020:Morphine; D002766:Cholecystokinin; D010634:Phenobarbital